Hematol Oncol. 2020 Aug 3. doi: 10.1002/hon.2785. Online ahead of print.
To better understand the expression of cancer testis antigens (CTA) and its association with clinical outcomes on patients with T-cell lymphomas, we sought to establish a baseline level of expression of CTA across a diversity of PTCL subtypes. Lymphoma specimens were acquired through routine clinical care and adequate samples were selected for the creation of a tissue microarray. CTA expression for survivin, SCP1, WT1, PLAC1, SSX2, and PRAME, were evaluated by immunohistochemistry. Over a period
of 25 years, 40 patient samples with sufficient quality material from patients with PTCL were included in the analysis. Thirty-nine (98%) patients expressed at least one of the target CTA. Survivin, SCP1, and WT1 were expressed on 98%, 12.5%, and 5% of PTCL samples, respectively. Six (15%) patients expressed two or more CTA. We present these data on baseline expression of CTA in order to inform future research exploring strategies to target and modulate the expression of these antigens for therapeutic purposes. This article is protected by copyright. All rights reserved.